Abacavir has been studied since the mid-1990s. The evidence on effectiveness is settled, one major safety problem was solved outright, and a second question has been argued over for nearly two decades without full resolution.
What established it as treatment?
Registration trials showed abacavir-containing combinations achieving durable viral suppression, and it became a standard nucleoside backbone alongside lamivudine. Later studies established the combination with dolutegravir as a single-tablet regimen, which is how most people now take it.
Is it as effective as tenofovir?
Broadly comparable in most people. Some earlier studies suggested abacavir with lamivudine performed less well in people starting with a very high viral load, which influenced prescribing for a period. Combining it with a potent third agent such as dolutegravir has largely addressed that concern.
What did the PREDICT study show?
That screening for the HLA-B*5701 gene variant before prescribing essentially eliminates clinically confirmed hypersensitivity reactions. It is one of the clearest demonstrations of pharmacogenetic testing changing practice, and it converted abacavir from a drug with a dangerous unpredictable reaction into one with a manageable known risk.
How common is the variant?
It varies considerably between populations, being more common in people of European descent and less so in some other groups. Because the variation is substantial and individual ancestry is a poor predictor, everyone is tested regardless.
What is the cardiovascular question?
Some large observational cohorts, notably the D:A:D study, found an association between recent abacavir use and myocardial infarction. Other analyses, including some randomised trial data, have not found the same signal.
Why has it not been resolved?
Because observational data cannot easily separate the drug from the reasons it was prescribed. Abacavir was often chosen for people with kidney problems, who tend to have more cardiovascular risk anyway. Disentangling that from a true drug effect has proved difficult.
What do clinicians do with that?
Weigh it. Most guidelines suggest caution in people with substantial existing cardiovascular risk while not excluding it outright. For someone with no such risk factors, it is generally not considered a barrier.
What about long-term safety otherwise?
Reassuring. Unlike the older thymidine analogues, abacavir does not cause significant mitochondrial toxicity, fat loss or peripheral neuropathy. Long-term cohorts have not identified kidney or bone effects attributable to it.
What about resistance?
Resistance develops through accumulated mutations rather than a single one, and it overlaps partially with resistance to other nucleoside analogues. Its resistance profile is assessed alongside its partner drugs rather than in isolation.
What is still being studied?
Mainly the cardiovascular question, through ongoing cohort work, and the performance of abacavir-based single-tablet regimens over longer periods. Neither is likely to change practice dramatically.
Where can you read the evidence yourself?
NAM aidsmap summarises HIV research reliably and without overstatement, and the British HIV Association publishes the guidelines UK clinicians follow. Both are freely available and more useful than a general search, which tends to surface material from other countries with different practice.
What does real-world data show?
Broadly consistent with the trials. Cohorts following people on abacavir-based regimens for years report durable suppression and low discontinuation. Since genetic screening became universal, hypersensitivity has largely disappeared from the picture.
Does the evidence apply to you?
Trials recruit particular populations and transfer best to people who resemble them. Whether the cardiovascular signal applies to your own risk profile is a fair question to put to a clinician rather than something to settle from a summary.
How do trials differ from real life?
Trial participants are monitored closely, reminded about appointments and selected for having few other conditions. Real-world results for abacavir are usually slightly less impressive as a consequence, and the gap reflects the setting rather than the drug.
Where does the funding come from?
Much antiretroviral research is industry-funded, which is normal and worth knowing. Independent cohort studies and guideline committees exist partly to scrutinise it, and findings about abacavir that appear across both are the most reliable.